Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 18, 2017 - Issue sup1: Edaravone (MCI-186) in Amyotrophic Lateral Sclerosis (ALS). Guest Editor: Angela Genge
Submit an article Journal homepage
2,926
Views
14
CrossRef citations to date
0
Altmetric
Research Article

A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies

Alexander KalinMitsubishi Tanabe Pharma Development America, Inc, Jersey City, NJ, USA, and Correspondence[email protected]
,
Elvia Medina-ParaisoMitsubishi Tanabe Pharma Development America, Inc, Jersey City, NJ, USA, and
,
Kaoru IshizakiMitsubishi Tanabe Pharma Corporation, Tokyo, Japan
,
Alex KimMitsubishi Tanabe Pharma Development America, Inc, Jersey City, NJ, USA, and
,
Yannong ZhangMitsubishi Tanabe Pharma Development America, Inc, Jersey City, NJ, USA, and
,
Takanori SaitaMitsubishi Tanabe Pharma Development America, Inc, Jersey City, NJ, USA, and
&
Masahiko WasakiMitsubishi Tanabe Pharma Corporation, Tokyo, Japan
 show all
Pages 71-79 | Received 20 Apr 2017, Accepted 27 Jul 2017, Published online: 05 Sep 2017

References

  • Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942–55.
  • Rascovsky K, Xie S, Boller A, Han X, McCluskey L, Elman L, et al. Subscales of the ALS functional rating scale (ALSFRS-R) as determinants of survival in amyotrophic lateral sclerosis (ALS). Poster session presented at: Anterior Horn Cell Disease, Biomarker. 66th Annual meeting of American Academy of Neurology: 2014 April 27-May 2; Philadelphia, PA.
  • Rudnicki S, Al-Lahham T, Gundogdu B, Limaye K, Mahuwala Z, Williams H. Is worse prognosis in older ALS patients more than just a matter of years? Poster session presented at: ALS Imaging, Biomarkers, and Clinical Testing. 67th Annual meeting of American Academy of Neurology: 2015 April 18–24; Washington, DC.
  • Jordan H, Fagliano J, Rechtman L, Lefkowitz D, Kaye W. Effects of demographic factors on survival time after a diagnosis of amyotrophic lateral sclerosis. Neuroepidemiology. 2015;44:114–20.
  • Paulukonis ST, Roberts EM, Valle JP, Collins NN, English PB, Kaye WE. Survival and cause of death among a cohort of confirmed amyotrophic lateral sclerosis cases. PLoS One. 2015;10:e0131965.
  • Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310–23.
  • Watanabe T, Yuki S, Egawa M, Nishi H. Protective effects of MCI-186 on cerebral ischemia (possible involvement of free radical scavenging and antioxidant actions). J Pharmacol Exp Ther. 1994;268:1597–604.
  • Yamamoto T, Yuki S, Watanabe T, Mitsuka M, Saito KI, et al. Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Res. 1997;762:240–2.
  • Mizuno A, Umemura K, Nakashima M. Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion. Gen Pharmacol. 1998;30:575–8.
  • Lee BJ, Egi Y, van Leyen K, Lo EH, Arai K. Edaravone, a free radical scavenger, protects components of the neurovascular unit against oxidative stress in vitro. Brain Res. 2010;1307:22–7.
  • Miyamoto N, Maki T, Pham LD, Hayakawa K, Seo JH, Mandeville ET, et al. Oxidative stress interferes with white matter renewal after prolonged cerebral hypoperfusion in mice. Stroke. 2013;44:3516–21.
  • Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler. 2006;7:241–5.
  • Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610–17.
  • The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well-defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.
  • The Writing Group for the Edaravone (MCI-186) ALS 18 Study Group. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS Severity Classification: Grade 3, requiring assistance for eating, excretion or ambulation). Amyotroph Lateral Scler Frontotemporal Degener. 2017;18 (Suppl). [Epub ahead of print]. doi:10.1080/21678421.2017.1361441

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.